GlassScriptPhysician profile
Sung Hee An
NPI 1861066508
$8,665.51
in general payments reported to CMS, 2019-2025
55 companies · $2,805 in 2025
The $2,805 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $891 · 2022: $1,987 · 2023: $1,162 · 2024: $1,820 · 2025: $2,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,788.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,920.76 | 2021-2025 | |
| Ucb, INC. | $846.69 | 2023-2025 | Briviact, Nayzilam, Rystiggo |
| Amarin Pharma, INC. | $543.55 | 2021-2023 | |
| Lundbeck LLC | $409.80 | 2023-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $365.80 | 2023-2025 | |
| Lilly USA, LLC | $298.85 | 2021-2025 | Emgality, Amyvid, Jardiance |
| Neurocrine Biosciences, INC. | $292.38 | 2023-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $285.32 | 2023-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $273.26 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $203.02 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $184.53 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $183.87 | 2023-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Amgen INC. | $180.47 | 2021-2023 | Prolia, Evenity |
| Teva Pharmaceuticals USA, INC. | $164.00 | 2023-2024 | Austedo Xr |
| Gilead Sciences, INC. | $163.86 | 2021-2023 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sung Hee An listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.